［1］MILLER KD,NOGUEIRA L,MARIOTTO AB,et al.Cancer treatment and survivorship statistics,2019［J］.CA Cancer J Clin,2019,69(5):363-385.
［2］IBRAGIMOVA M,TSGANOV M,LITVIAKOV N.Tumour stem cells in breast cancer［J］.Int J Mol Sci,2022,23(9):5058.
［3］STEINBICHLER TB,SAVIC D,DUDAS J,et al.Cancer stem cells and their unique role in metastatic spread［J］.Semin Cancer Biol,2020,60:148-156.
［4］CHEN WM,ZHANG L,LIU SL,et al.Advances in biomarkers and endogenous regulation of breast cancer stem cells［J］.Cells,2022,11(19):2941.
［5］陈杰,廖成成,陈智威,等.膀胱癌干细胞标志物及相关信号通路：抗体靶向治疗思路［J］.中国组织工程研究,2021,25(19): 3090-3096.
CHEN J,LIAO CC,CHEN ZW,et al.Stem cell markers and related signaling pathways in bladder cancer:ideas for antibody-targeted therapy［J］.China Tissue Engineering Research,2021,25(19): 3090-3096.
［6］SIN WC,LIM CL.Breast cancer stem cells-from origins to targeted therapy［J］.Stem Cell Investig,2017,4(11):96.
［7］刘占伟,李永安.肿瘤干细胞在乳腺癌发生发展中的作用机制研究进展［J］.癌症进展,2016,14(3):205-207.
LIU ZW,LI YA.Research progress on the mechanism of the role of tumor stem cells in breast cancer development［J］.Cancer Progress,2016,14(3):205-207.
［8］ARAMINI B,MASCIALE V,ARIENTI C,et al.Cancer stem cells (CSCs),circulating tumor cells (CTCs) and their interplay with cancer associated fibroblasts (CAFs): A new world of targets and treatments［J］.Cancers (Basel),2022,14(10):2408.
［9］ARAMINI B,MASCIALE V,GRISENDI G,et al.Dissecting tumor growth:The role of cancer stem cells in drug resistance and recurrence［J］.Cancers (Basel),2022,14(4):976.
［10］VAN ANDEL H,KOCEMBA KA,SPAARGAREN M,et al.Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options［J］.Leukemia,2019,33(5):1063-1075.
［11］HU X,ZHANG Q,XING WY,et al.Role of microRNA/lncRNA intertwined with the Wnt/β-catenin axis in regulating the pathogenesis of triple-negative breast cancer［J］.Front Pharmacol,2022,13:814971.
［12］LI MW,HAN YZ,ZHOU HZ,et al.Transmembrane protein 170B is a novel breast tumorigenesis suppressor gene that inhibits the Wnt/β-catenin pathway［J］.Cell Death Dis,2018,9(2):91.
［13］GYU BJ,JI YK,SUNG DC,et al.Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype［J］.Sci Rep,2015,5(1):12465.
［14］DO YK,EUN YP,EUN SC,et al.A novel miR-34a target,protein kinase D1,stimulates cancer stemness and drug resistance through GSK3/β-catenin signaling in breast cancer［J］.Oncotarget,2016,7(12):14791-14802.
［15］XIN W,YOUN SJJ,SOHEE J,et al.PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness［J］.Nat Commun,2016,(1):10633.
［16］GUJRAL TS,CHAN M,PESHKIN L,et al.A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis［J］.Cell,2014,159(4):844-856.
［17］SALE S,LAFKAS D,ARTAVANIS-TSAKONAS S.Notch2 genetic fate mapping reveals two previously unrecognized mammary epithelial lineages［J］.Nat Cell Biol,2013,15(5):451-460.
［18］WALCHER L,KISTENMACHER AK,SUO H,et al.Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies［J］.Front Immunol,2020,11:1280.
［19］MCGOWAN PM,SIMEDREA C,RIBOT EJ,et al.Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer［J］.Mol Cancer Res,2011,9(7):834-844.
［20］JIANG N,HU Y,WANG M,et al.The notch signaling pathway contributes to angiogenesis and tumor immunity in breast cancer［J］.Breast Cancer (Dove Med Press),2022,14:291-309.
［21］DANGELO RC,OUZOUNOVA M,DAVIS A,et al.Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity［J］.Mol Cancer Ther,2015,14(3):779-787.
［22］RYOO IG,CHOI BH,KWAK MK.Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells［J］.Oncotarget,2015,6(10):8167-8184.
［23］MITSUISHI Y,TAGUCHI K,KAWATANI Y,et al.Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming［J］.Cancer Cell,2012,22(1):66-79.
［24］BAI XP,CHEN YB,HOU XY,et al.Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters［J］.Drug Metab Rev,2016,48(4):541-567.
［25］MIRICESCU D,TOTAN A,STANESCU-SPINU II,et al.PI3K/AKT/mTOR signaling pathway in breast cancer:from molecular landscape to clinical aspects［J］.Int J Mol Sci,2020,22(1):173.
［26］BERENJENO IM,PINEIRO R,CASTILLO SD,et al.Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling［J］.Nat Commun,2017,8(1):1773.
［27］LIU NM,WANG XH,LI X,et al.Identification of effective natural PIK3CA H1047R inhibitors by computational study［J］.Aging (Albany NY),2021,13(16):20246-20257.
［28］ZHU KR,WU YQ,HE P,et al.PI3K/AKT/mTOR-targeted therapy for breast cancer［J］.Cells,2022,11(16):2508.
［29］POSADA IMD,LECTEZ B,SHARMA M,et al.Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner［J］.Oncotarget,2017,8(27):44550-44566.
［30］KUEHN J,ESPINOZA-SANCHEZ NA,TEIXEIRA FCOB,et al.Prognostic significance of hedgehog signaling network-related gene expression in breast cancer patients［J］.J Cell Biochem,2021,122(5):577-597.
［31］GIAMMONA A,CRIVARO E,STECCA B.Emerging roles of hedgehog signaling in cancer immunity［J］.Int J Mol Sci,2023,24(2):1321.
［32］张领衔,蔡车国.乳腺发育与乳腺干细胞的分子调控［J］.厦门大学学报(自然科学版),2022,61(03):415-428.
ZHANG LX,CAI CG.Molecular regulation of mammary gland development and breast stem cells［J］.Journal of Xiamen University (Natural Science Edition),2022,61(03):415-428.
［33］KE Z,CAIPING S,QING Z,et al.Sonic hedgehog-Gli1 signals promote epithelial-mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway［J］.Med Oncol,2015,32(1):368.
［34］FAN HX,WANG S,ZHAO H,et al.Sonic hedgehog signaling may promote invasion and metastasis of oral squamous cell carcinoma by activating MMP-9 and E-cadherin expression［J］.Med Oncol,2014,31(7):41.
［35］GWAK JM,KIM M,KIM HJ,et al.Expression of embryonal stem cell transcription factors in breast cancer:Oct4 as an indicator for poor clinical outcome and tamoxifen resistance［J］.Oncotarget,2017,8(22):36305-36318.
［36］BHATT S,STENDER JD,JOSHI S,et al.OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells［J］.Oncogene,2016,35(44):5722-5734.
［37］ZHAI YZ,HAN YJ,HAN ZQ.Aberrant expression of WWOX and its association with cancer stem cell biomarker expression［J］.Int J Clin Exp Pathol,2020,13(5):1176-1184.
［38］柴效科,周聪,宋爱琳.SOX2在乳腺癌中的研究进展［J］.现代肿瘤医学,2021,29(21):3880-3884.
CHAI XK,ZHOU C,SONG AL.Progress of SOX2 in breast cancer ［J］.Modern Oncology,2021,29(21):3880-3884.
［39］JIANG HM,ZHOU C,ZHANG Z,et al.Jagged1-Notch1-deployed tumor perivascular niche promotes breast cancer stem cell phenotype through Zeb1［J］.Nat Commun,2020,11(1):5129.
［40］吴宏培,李俊海,廖和和，等.三阴性乳腺癌中ZEB1表达与临床病理及预后的关系［J］.现代肿瘤医学,2016,24(13): 2067 -2069.
WU HP,LI JH,LIAO HH,et al.Association of ZEB1 expression with clinicopathology and prognosis in triple-negative breast cancer［J］.Modern Oncology,2016,24(13):2067 -2069.
［41］BANERIEE S,LO WC,MAJUMDER P,et al.Multiple roles for basement membrane proteins in cancer progression and EMT［J］.Eur J Cell Biol，2022,101(2):151220.
［42］PANAGIOTOU E,SYRIGOS NK,CHARPIDOU A,et al.CD24:A novel target for cancer immunotherapy［J］.J Pers Med，2022,12(8):1235.
［43］SCHABATH H,RUNZ S,JOUMAA S,et al.CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells［J］.J Cell Sci,2006,119(2):314-325.
［44］BENSIMON J,ALTMEYER-MOREL S,BENJELLOUN H,et al. CD24(-/low) stem-like breast cancer marker defines the radiation-resistant cells involved in memorization and transmission of radiation-induced genomic instability［J］.Oncogene,2013,32(2):251-258.
［45］KESHARWANI P,CHADAR R,SHEIKH A,et al.CD44-targeted nanocarrier for cancer therapy［J］.Front Pharmacol,2022,12:800481.
［46］张瑞娟,杨英.CD44表达对乳腺癌干细胞的影响［J］.中国生物制品学杂志,2021,34(11):1387-1390.
ZHANG RJ,YANG Y.Effect of CD44 expression on breast cancer stem cells［J］.Chinese Journal of Biological Products,2021,34(11):1387-1390.
［47］ESCUDERO ML,SRINIVASAN M,HAMOUDA RK,et al.Evaluation of CD44+/CD24- and aldehyde dehydrogenase enzyme markers in cancer stem cells as prognostic indicators for triple-negative breast cancer［J］.Cureus,2022,14(8):e28056.
［48］毕晓娟,付明刚,郭丽英,等.来源于乳腺癌正常组织乳腺干细胞的安全性［J］.中国组织工程研究,2016,20(41):6125-6130.
BI XJ,FU MG,GUO LY,et al.Safety of breast stem cells derived from normal breast cancer tissue［J］.Chinese Tissue Engineering Research,2016,20(41):6125-6130.
［49］牛喜梅,王爱玲,马颖颖,等.肿瘤相关成纤维细胞在乳腺癌中的研究进展［J］.医学综述,2022,28(04):700-705.
NIU XM,WANG AL,MA YY,et al.Advances in the study of tumor-associated fibroblasts in breast cancer［J］.Medical Review,2022,28(04):700-705.
［50］VIEIRA AF,RIBEIRO AS,DIONISIO MR,et al.P-cadherin signals through the laminin receptor α6β4 integrin to induce stem cell and invasive properties in basal-like breast cancer cells［J］.Oncotarget,2014,5(3): 679-692.
［51］VIEIRA AF,PAREDES J.P-cadherin and the journey to cancer metastasis［J］.Mol Cancer,2015,14(1):178.
［52］PAREDES J,ALBERGARIA A,OLIVEIRA JT,et al.P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation［J］.Clin Cancer Res,2005,11(16):5869-5877.
［53］RUBTSOVA SN,ZHITNYAKIY,GLOUSHANKOVA NA.Dual role of E-cadherin in cancer cells［J］.Tissue Barriers,2022,10(4):2005420.
［54］RUAN YS,CHEN LB,XIE DF,et al.Mechanisms of cell adhesion molecules in endocrine-related cancers:A concise outlook［J］.Front Endocrinol (Lausanne),2022,13:865436.
［55］VIEIRA AF,RIBEIRO AS,DIONSIO MR,et al.P-cadherin signals through the laminin receptor α6β4 integrin to induce stem cell and invasive properties in basal-like breast cancer cells［J］.Oncotarget,2014,5(3):679-692.
［56］BRUGNOLI F,GRASSILLI S,ALQASSAB Y,et al.CD133 in breast cancer cells: More than a stem cell marker［J］.J Oncol,2019,2019:7512632.
［57］JOSEPH C,ARSHAD M,KUROZOMI S,et al.Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer［J］.Breast Cancer Res Treat,2019,174(2):387-399.
［58］WRIGHT MH,CALCAGNO AM,SALCIDO CD,et al.Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics［J］.Breast Cancer Res,2008,10(1):10.
［59］CROKER AK,GOODALE D,CHU J,et al.High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability［J］.J Cell Mol Med,2009,13(8B):2236-2252.
［60］BRUGNOLI F,GRASSILLI S,PIAZZI M,et al.In triple negative breast tumor cells,PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness［J］.Mol Cancer,2013,12(1):165.
［61］KATOH M.Canonical and non-canonical Wnt signaling in cancer stem cells and their niches:Cellular heterogeneity,omics reprogramming,targeted therapy and tumor plasticity (Review)［J］.Int J Oncol,2017,51(5):1357-1369.
［62］BARZAMAN K,VAFAEI R,SAMADI M,et al.Anti-cancer therapeutic strategies based on HGF/MET,EpCAM,and tumor-stromal cross talk［J］.Cancer Cell Int,2022,22(1):259.
［63］VENETIS K,CRIMINI E,SAJJADI E,et al.HER-2 Low,low, ultra-low, and novel complementary biomarkers: expanding the spectrum of her2 positivity in breast cancer［J］.Front Mol Biosci,2022,9:834651.
［64］郑维锋,卢创新,杨争艳.HER-2阳性乳腺癌靶向药物的研究进展［J］.中国肿瘤生物治疗杂志,2022,29(06):587-595.
ZHENG WF,LU CX,YANG ZY.Research progress of targeted drugs for HER-2-positive breast cancer［J］.Chinese Journal of Tumor Biotherapy,2022,29(06):587-595.
［65］DURU N,CANDAS D,JIANG GC,et al.Breast cancer adaptive resistance:HER-2 and cancer stem cell repopulation in a heterogeneous tumor society［J］.J Cancer Res Clin Oncol,2014,140(1):1-14.
［66］GINESTIER C,LIU SL,DIEBEL ME,et al.CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts［J］.J Clin Invest,2010,120(2):485-497.
［67］SINGH JK,FARNIE G,BUNDRED NJ,et al.Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER-2 via HER-2-dependent and -independent mechanisms［J］.Clin Cancer Res,2013,19(3):643-656.